This page shows the latest Acadia news and features for those working in and with pharma, biotech and healthcare.
In 2016, Acadia won US Food and Drug Administration (FDA) approval for Nuplazid as a treatment for Parkinson’s disease-associated psychosis, the first therapy approved in this setting. ... The schizophrenia trial, like the MDD trial, was viewed as one
This includes Sage Therapeutics, Acadia Pharmaceutical, Karuna Therapeutics and even Biogen, which is looking for approval of its controversial Alzheimer’s drug.
The drug has failed the late-stage ENHANCE trial in schizophrenia inadequately controlled by currently-approved drugs, viewed as one of Acadia’s biggest opportunities to extend the franchise. ... Shares in Acadia were down 16% remarket in the wake of
s board in May having previously had a 15-year stint as CEO of Acadia Pharma which came to end in 2015 after the company was forced to delay a filing
Concludes Acadia Pharmaceuticals’ drug provides ‘modest but meaningful’ benefits. Acadia Pharmaceuticals is celebrating an FDA panel verdict that could set its Nuplazid drug up to be the first approved therapy for ... However, there were some
AGN 203818 is an orally active, α-adrenoreceptor agonist that was discovered as part of a research programme between Allergan and ACADIA.
More from news
Approximately 3 fully matching, plus 5 partially matching documents found.
Jacob Plieth at Vantage recently highlighted this trend, with companies like Tesaro, Clovis Oncology and Acadia failing to meet revenue expectations for their new launches.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
US biopharmaceutical company Acadia Pharmaceuticals has appointed Damien McDevitt (pictured) as senior vice president of corporate development. ... Meanwhile, Acadia’s SVP, technology development and operations Jim Nash will retire in January.
Dr Gray has over 20 years of biotechnology and biopharmaceutical experience and is the owner and president of Gray Strategic Advisors as well as serving on the boards of Acadia Pharmaceuticals,
He moves to the San Diego biopharma from Alkermes. San Diego biopharmaceutical company Acadia Pharmaceuticals has appointed Srdjan (Serge) Stankovic as executive vice president, head of research and development. ... Steve Davis, Acadia's president
More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...